Latest clinical research confirms that IQOS reduces smoker exposure to select harmful chemicals as compared to cigarette smoke
March 27 2017 - 5:00AM
Business Wire
Studies conducted to date clearly indicate
that IQOS is likely to present less risk of harm compared to
smoking
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM)
today announces the positive results from an advanced clinical
study on IQOS, the company’s first electronically heated tobacco
product, published in the peer-reviewed journal Nicotine &
Tobacco Research.
Conducted in Japan over a three-month period by the well-known
clinical research organization, the Osaki Hospital Tokyo Heart
Center, the study showed that smokers who switched to IQOS:
- Reduced their exposure to 15 harmful
chemicals to levels that approached those of smokers who quit
smoking;
- Showed improvements in measured health
indicators specific to smoking-related diseases, such as lung and
heart disease. In all cases, the health indicators improved in the
same direction as seen in smokers who quit. Further testing through
a longer-term study is underway; and
- Found the product satisfying and were
likely to completely switch to it.
The research was conducted in line with internationally
respected guidelines for clinical trials, such as Good Clinical
Practice as defined by the International Conference for
Harmonization of Technical Requirements for Pharmaceuticals for
Human Use. 160 smokers were divided into three groups: continued
smoking, quitting, and complete switching to IQOS. Participants
spent five days at a clinic and continued the experiment at home
for an additional 85 days, during which time biological samples and
measurements were regularly taken.
PMI’s research program to confirm the risk reduction potential
of IQOS includes laboratory and clinical studies, research on
actual product use, and evaluation of how well smokers understand
communications related to reduced risk. This and a related study
are the latest of an eight-part clinical research program completed
on IQOS to support reduced exposure and preliminary improvements in
health outcomes. A one-year study with about 1,000 participants is
currently ongoing to further support the current strong indications
of risk reduction.
PMI’s Chief Medical Officer, Dr. Frank Lüdicke, said: “This
study is an important step to confirm that while IQOS is not
risk-free, it is a better choice for the millions of smokers who do
not quit. It clearly indicates that smokers who switch to IQOS
reduce their exposure to harmful compounds to levels that approach
those of smokers who quit smoking. The study also clearly indicates
areas of significant risk reduction which we are currently
confirming through a longer term study.”
PMI is committed to replacing cigarettes with smoke-free
products as soon as possible to the benefit of smokers, society and
public health. Over 1.4 million smokers have already switched to
IQOS, and the company has plans to expand commercialization to key
cities in 30-35 countries by the end of 2017. Since 2008, PMI has
hired over 400 scientists and experts and invested over USD 3
billion in research, development and early commercialization for
its portfolio of smoke-free products. The company has published
over 200 peer-reviewed publications and book chapters in the past
ten years.
The study is available on www.pmiscience.com.
###
Philip Morris International Inc.
Philip Morris International Inc. (PMI) is the world’s leading
international tobacco company, with six of the world's top 15
international brands and products sold in more than 180 markets. In
addition to the manufacture and sale of cigarettes, including
Marlboro, the number one global cigarette brand, and other tobacco
products, PMI is engaged in the development and commercialization
of Reduced-Risk Products (RRPs). RRPs is the term PMI uses to refer
to products that present, are likely to present, or have the
potential to present less risk of harm to smokers who switch to
these products versus continued smoking. Through multidisciplinary
capabilities in product development, state-of-the-art facilities,
and industry-leading scientific substantiation, PMI aims to provide
an RRP portfolio that meets a broad spectrum of adult smoker
preferences and rigorous regulatory requirements. For more
information, see www.pmi.com and www.pmiscience.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170327005401/en/
Media enquiriesPhilip Morris International media officeT: +41
(0)58 242 4500E: media@pmi.com
Philip Morris (NYSE:PM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Philip Morris (NYSE:PM)
Historical Stock Chart
From Sep 2023 to Sep 2024